Amwell reports Q1 EPS (25c), consensus (19c)

Reports Q1 revenue $59.5M, consensus $60.52M…”In Q1, we made significant strides forward. We are completing critical milestones to deploy our solution for the Military Health System, working alongside the Leidos Partnership for Defense Health. We also successfully migrated a large portion of our visit volume onto our Converge platform via some of our most strategic payer clients,” said Ido Schoenberg, M.D., chairman and CEO of Amwell. “Our sales transformation is empowering our teams with a robust enterprise selling motion that we believe will return us to growth, fueled by demand for our hybrid care expertise and our technology offering.” Schoenberg continued, “We are putting our re-platforming behind us and are optimizing our cost structure. We continue into 2024 with growing conviction around the value we deliver to our clients and the profitable growth that we aim to achieve.”